HOCK CHEMIE INNOTECH LIMITED is one of innovative pioneers in manufacturing personal cosmetics materials. Our objective is to provide high quality cosmetics raw materials and services for global clients. We aim to innovate with advanced technology and grasp the market trend through utilizing our strong commercial experience and technical expertise to manufacture more and better raw materials and formulations. In order to let our clients be the forefront of the trend, we try our best to provide professional technical solutions, bring sensory feeling of personal innovation and create good products to satisfy your requirements. We will create infinite possibility with you together for the bright future of cosmetics industry.
HKSTP x ARROW HARDWARE LAB
HKSTP x ARROW Hardware Lab is designed to accelerate market-ready microelectronic innovations. Supported by Arrow Electronics industry experts and global partners, we offer extensive insights and business networks to inspire and elevate unique product development. Together, we spark the next wave of innovation, from chips to products.
HKUBio – Hong Kong Universal Biologicals Company Limited
Hong Kong Universal Biologicals Company Limited (HKUBio) is a Hong Kong -based biotech R&D Company, spinoff from The University of Hong Kong (HKU), Centre for Virology, Vaccinology and Therapeutics (CVVT) (InnoHK@HKUMed), and in collaboration with The State Key Laboratory for Emerging Infectious Diseases (SKLEID) of the Department of Microbiology at the University of Hong Kong. We set up at the Hong Kong Science Park in developing innovative vaccine products, possesses the Viral Vector Vaccines Technology system (DelNS1), along with a series of patents for developing intranasal vaccines for respiratory viruses. This technology platform is based on a flu-based viral vector and can be utilized for creating vaccines for flu, COVID-19, and other respiratory viral diseases. The first intranasal spray vaccine for COVID-19 developed using this technology platform has been approved for human use in mainland China in 2022. One of the unique advantages of this vaccine system is its ability to combine vaccines for flu and other respiratory viral infections, inducing both systemic and mucosal immunity, a feat not achievable by other intramuscularly injected vaccines. This platform technology was awarded the Gold Medal with Congratulations of the Jury” the Special Edition 2021 Inventions Geneva Evaluation Days The platform of the DelNS1 vaccine system technology has been utilized to generate vaccines for seasonal influenza, COVID-19, Flu-COVID (a combination vaccine for flu and COVID-19 in a single composition), Flu-RSV (a combination vaccine for flu and RSV in a single composition), and Flu-hMPV (a combination vaccine for flu and hMPV in a single composition). Our showcase will highlight the technology and the development of vaccine candidates for a variety of common cold viruses. The DelNS1-RBD vaccine for COVID-19 based on this technology has successfully completed all phases of clinical trials and has received approval for human use in China in 2022. Development is underway for vaccines targeting influenza and RSV, with plans to enter investigational new drug (IND) status within one to two years. Additionally, a vaccine candidate for the potential emerging H5N1 virus has been created and will undergo evaluation in humans to facilitate technology stockpiling for pandemic preparedness. Concurrently, a series of vaccines for common cold viruses are in development and are slated for human evaluation within the next 3-5 years through collaborative efforts with other partners. This technology focuses on Life and Health Technology R&D. Given the impact of the COVID-19 pandemic and the efficient transmission of SARS-CoV-2, The development of effective vaccines that can induce both systemic and mucosal immunity is considered to be the focus of the next generation of vaccines for respiratory viruses. The technology showcased here is exceptionally innovative as it can be integrated with flu vaccines to target other respiratory viral infections. Its practicality is underscored by successful human trials and the approval of a product based on this technology for human use.
Haylo Tech Limited
Haylo is an AI-powered wearable headband designed to support focus and retention for neurotypical and neurodivergent learners who struggle with traditional screen-based tools. Students interact with voice-first AI with captured video as the context
Hay-koze Limited
Haykozé crafts Life Care Widgets for all to enjoy life with greater agility and freedom. Our Air Ring 49 (AR49) is the world’s first contactless biomedical cooling accessory for headgears, to reduce heatstrokes, recover expensive hours of productivity and enable agile lifestyles worldwide.
Greenbulb Trading Limited
Founded in 2004, GreenBulb creates innovative lifestyle and tech products that turn ideas into marketable realities. We’re passionate about smart design, clever gadgets, and sustainable solutions that reshape everyday experiences. Our creations have been featured in leading media including The Verge, Engadget, and Cult of Mac.
Green Vigor Limited
We are the 1st in the world to recycle hydropower in buildings’ water tank. With patented, novel, modular and on-site HydroVigor ®- hydropower recycle system, we aim to unlocking urban building water tank to be Hydropower plant when everyone using water.
Great Bay Bio
Great Bay Bio, headquartered in Hong Kong, was founded in 2019 with extensive footprint in the Greater Bay Area. Adhering to the corporate vision of “Global Bioprocessing Made Simpler and More Efficient”, GBB is committed to applying AI and other cutting-edge technologies to promote bioprocessing innovations, thus solve pain points, such as long timelines, high cost and low success rate, in drug development. GBB takes improving human life, health and value as its long-term goal. We have platforms available: 1. AlfaDAX: AI + antibody developability assessment and optimization. 2. AlfaCell: AI + site-specific integration: Titer is guarantee 5 g/L for mAb and BsAb. From DNA to RCB only takes 1.5 months. The IND process can be saved up to 6 months. 3. AlfaOPA: AI + cell culture development without media screening: be able to develop the cell culture media within 1 month and the titer can be increased by more than 30%. | Great Bay Bio (GBB), headquartered in HKSTP, is a biotech company that drives drug development using cutting-edge technologies such as AI, big data mining, and automation. GBB adheres to the corporate vision of “Global Bioprocessing Made Simpler and More Efficient,” and aims to address the challenges of long timelines, high costs, and low success rates in drug development, with a long-term goal of enhancing human life, health, and value. The core team of GBB comprises experts from medicine, synthetic biology, and artificial intelligence. The company operates a 3,000㎡ R&D laboratory and CMC platform, supporting customers in securing clinical trial approvals from China’s NMPA and the US FDA. GBB has secured nearly 100 patents related to AI-enabled drug development and successfully commercialized multiple AI technology platforms. The company has established long-term partnerships with leading domestic and international enterprises. GBB has passed the ISO 9001:2015 quality management system certification, been selected for Forbes Asia 100 to Watch 2024 List, and won numerous awards, including “Deloitte Technology Rising Star Company,” “EY Entrepreneur Of The Year,” “15th Shenzhen Innovation & Entrepreneurship Competition,” “Gold Award for Hong Kong Global Innovation,” “Excellence in Process Innovation Award,” and “Excellence in Technology Adoption Award”. The company has also been successfully selected for the Hong Kong Science Park Elite Enterprise Program.